Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity

P. Taborska, D. Stakheev, D. Smrz

. 2026 ; 31 (2) : 78. [pub] 20251216

Status neindexováno Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc26001545

Soft tissue sarcomas are therapeutically challenging. Among soft tissue sarcoma subtypes, undifferentiated pleomorphic sarcoma (UPS) exhibits one of the most pronounced disparities between its comparatively higher responsiveness to immunotherapy and its limited responsiveness to conventional cytotoxic chemotherapy. The interplay between immunotherapy and cytotoxic chemotherapy is still largely unknown. Interferon-γ (IFNγ) is a key player in antitumor immunity and contributes to the modulation of the tumor microenvironment, which impacts both immune and cancer cells. The mechanism by which this interplay can affect cancer cell chemosensitivity and immune sensitivity is difficult to predict. The present study aimed to investigate the interplay of IFNγ signaling in the UPS cell line JBT19. It was identified that IFNγ treatment significantly decreased the proliferation of JBT19 cells and increased the surface expression levels of cluster of differentiation (CD)44, CD47, CD95 (Fas), major histocompatibility complex (MHC)-I and programmed death-ligand 1 (PD-L1). In addition, IFNγ strongly upregulated surface expression levels of MHC-II and converted JBT19 cells into docetaxel-resistant cells. The IFNγ-induced changes were sustained but reversible after 3 weeks of cell culture without IFNγ. Regardless of IFNγ treatment, JBT19 cells could elicit and amplify the adaptive immune response in vitro. The in vitro JBT19-reactive lymphocytes effectively eliminated both IFNγ-treated and non-treated JBT19 cells, thus overcoming IFNγ-induced chemoresistance. To the best of our knowledge, the present study demonstrated a dual role of IFNγ towards cancer cell chemoresistance and immunostimulatory potential for the first time. The present study findings may have potential implications for combining immunotherapy with cytotoxic chemotherapy in cancer treatment in the future.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc26001545
003      
CZ-PrNML
005      
20260122082551.0
007      
ta
008      
260116s2026 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ol.2025.15431 $2 doi
035    __
$a (PubMed)41473700
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Taborska, Pavla $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
245    10
$a Dual role of IFNγ in reprogramming the undifferentiated pleomorphic sarcoma cell line JBT19 towards cytotoxic chemotherapy and antitumor immunity / $c P. Taborska, D. Stakheev, D. Smrz
520    9_
$a Soft tissue sarcomas are therapeutically challenging. Among soft tissue sarcoma subtypes, undifferentiated pleomorphic sarcoma (UPS) exhibits one of the most pronounced disparities between its comparatively higher responsiveness to immunotherapy and its limited responsiveness to conventional cytotoxic chemotherapy. The interplay between immunotherapy and cytotoxic chemotherapy is still largely unknown. Interferon-γ (IFNγ) is a key player in antitumor immunity and contributes to the modulation of the tumor microenvironment, which impacts both immune and cancer cells. The mechanism by which this interplay can affect cancer cell chemosensitivity and immune sensitivity is difficult to predict. The present study aimed to investigate the interplay of IFNγ signaling in the UPS cell line JBT19. It was identified that IFNγ treatment significantly decreased the proliferation of JBT19 cells and increased the surface expression levels of cluster of differentiation (CD)44, CD47, CD95 (Fas), major histocompatibility complex (MHC)-I and programmed death-ligand 1 (PD-L1). In addition, IFNγ strongly upregulated surface expression levels of MHC-II and converted JBT19 cells into docetaxel-resistant cells. The IFNγ-induced changes were sustained but reversible after 3 weeks of cell culture without IFNγ. Regardless of IFNγ treatment, JBT19 cells could elicit and amplify the adaptive immune response in vitro. The in vitro JBT19-reactive lymphocytes effectively eliminated both IFNγ-treated and non-treated JBT19 cells, thus overcoming IFNγ-induced chemoresistance. To the best of our knowledge, the present study demonstrated a dual role of IFNγ towards cancer cell chemoresistance and immunostimulatory potential for the first time. The present study findings may have potential implications for combining immunotherapy with cytotoxic chemotherapy in cancer treatment in the future.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stakheev, Dmitry $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
700    1_
$a Smrz, Daniel $u Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
773    0_
$w MED00193499 $t Oncology letters $x 1792-1082 $g Roč. 31, č. 2 (2026), s. 78
856    41
$u https://pubmed.ncbi.nlm.nih.gov/41473700 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20260116 $b ABA008
991    __
$a 20260122082536 $b ABA008
999    __
$a ok $b bmc $g 2470198 $s 1267262
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2026 $b 31 $c 2 $d 78 $e 20251216 $i 1792-1082 $m Oncology letters $n Oncol Lett $x MED00193499
LZP    __
$a Pubmed-20260116

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...